Premium
Induction of CD8 + T‐lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus
Author(s) -
Feng Carl G,
Blanchard Tom J,
Smith Geoffrey L,
Hill Adrian VS,
Britton Warwick J
Publication year - 2001
Publication title -
immunology and cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.999
H-Index - 104
eISSN - 1440-1711
pISSN - 0818-9641
DOI - 10.1046/j.1440-1711.2001.01042.x
Subject(s) - vaccinia , virology , mycobacterium tuberculosis , antigen , virus , tuberculosis , t lymphocyte , microbiology and biotechnology , lymphocyte , biology , cd8 , immunology , medicine , gene , recombinant dna , biochemistry , pathology
Protective immunity against Mycobacterium tuberculosis infection requires the activation of mycobacterium‐specific CD8 + T cells, as well as CD4 + T cells. Therefore, optimizing strategies that stimulate CD8 + T cells recognizing dominant mycobacterial antigens, including secreted proteins, may lead to the development of more effective vaccines against tuberculosis. To generate a viral vaccine that is safe in humans, the early secreted protein, MPT64, was expressed in the attenuated vaccinia virus (VV) strain, modified vaccinia virus Ankara (MVA‐64). The immunogenicity of MVA‐64 was compared with that of the Western Reserve strain of VV (VVWR‐64). The replication‐defective MVA‐64 was as efficient as VVWR‐64 in inducing specific antibodies and cytolytic T‐cell responses to a defined H‐2‐D b ‐restricted epitope on MTP‐64. In addition, priming with MPT64‐expressing plasmid DNA (DNA‐64), and boosting with either MVA‐64 or VVWR‐64, markedly enhanced MPT64‐specific cytolytic and IFN‐γ‐producing CD8 + T‐cell responses. These findings suggest that MVA may be a suitable vaccine carrier for stimulating mycobacterium‐specific CD8 + T‐cell responses and may be particularly relevant for developing vaccines for use in regions endemic for tuberculosis and HIV infection.